The therapeutic paradigm in oncology is undergoing a significant transformation led by antibody‑drug conjugates (ADCs) and bispecific antibodies (bsAbs). These antibody‑based platforms have expanded treatment options across both hematologic malignancies and solid tumors, delivering clinically meaningful activity in settings that were previously refractory to standard therapies. This review summarizes recent clinical advances, emerging targets, resistance mechanisms, and future directions for antibody‑based therapeutics.
ADCs have broadened the concept of actionable antigen expression. A leading example is trastuzumab deruxtecan, which extended the therapeutic window for HER2‑targeting by demonstrating efficacy in HER2‑low breast cancer and showing meaningful intracranial activity. These results have effectively redefined standards of care in selected HER2‑expressing populations and illustrate how ADCs can alter clinical definitions of targetability.
The ADC landscape continues to expand with novel targets under clinical evaluation, including TROP2, CLDN18.2, B7‑H3, and HER3. Development is also moving toward more complex formats, such as bispecific ADC constructs, which aim to refine tumor targeting and payload delivery. These innovations seek to enhance efficacy while improving the therapeutic index compared with first‑generation ADCs.
T‑cell‑engaging bsAbs have achieved deep and durable responses across multiple hematologic indications. Examples reported include CD20×CD3 constructs in B‑cell lymphomas, and BCMA×CD3 and GPRC5D×CD3 constructs in multiple myeloma. In acute lymphoblastic leukemia, CD19×CD3 bispecifics have produced substantial clinical activity. These agents have delivered meaningful responses even in heavily pretreated populations, establishing bsAbs as pivotal immunotherapeutic tools in hematology.
In solid tumors, bsAbs targeting pathways such as EGFR‑MET have shown clinically validated efficacy in historically refractory settings. DLL3‑targeted bispecific strategies also demonstrated activity, culminating in regulatory approval of tarlatamab for a difficult‑to‑treat indication. These developments confirm that T‑cell engagement can translate into meaningful outcomes beyond hematologic malignancies when appropriate targets are identified.
Despite clinical successes, several critical challenges remain. Antibody‑based agents have unique toxicity profiles that require specialized management. Resistance arises through mechanisms such as antigen escape and T‑cell exhaustion, which can limit durability of response. Additionally, there is an absence of validated predictive biomarkers to select patients most likely to benefit or to guide sequencing of therapies—an important unmet need for precision implementation.
How to optimally sequence ADCs, bsAbs, and chimeric antigen receptor (CAR) T‑cell therapies remains largely empirical. Clinical pathways for integrating these modalities with one another are not standardized, and evidence‑based algorithms for sequencing or combining therapies are lacking. Determining ideal sequencing will be essential to maximize patient benefit and manage cumulative toxicities.
Next‑generation approaches aim to address resistance and improve therapeutic indices. Strategies highlighted include bispecific ADCs that engage two antigens, probody‑drug conjugates that activate in the tumor microenvironment, and immune‑stimulating antibody conjugates that combine cytotoxic payloads with immune activation. Combining these novel constructs with existing immunotherapies is proposed to overcome resistance mechanisms such as antigen loss and T‑cell dysfunction.
Key unresolved questions include identification and validation of predictive biomarkers, optimal toxicity mitigation strategies, and evidence‑driven sequencing of ADCs, bsAbs, and CAR‑T approaches. Translating antibody‑based innovations into precision oncology will require clinical trials designed to address these gaps, comparative effectiveness studies, and mechanistic investigation of resistance. The review distills pivotal clinical data and outlines a roadmap to integrate next‑generation antibody therapeutics into practice.
The authors declared no competing interests. This review consolidates clinical advances and outstanding challenges related to ADCs and bsAbs across hematologic malignancies and solid tumors and was published in J Hematol Oncol (2026). DOI and PMID details are reported in the source.